Mesa Laboratories

MLAB

Market cap $523M

Lakewood, Colo., July 06, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 15, 2026, to shareholders of record at the close of business on August 31, 2026.

Mesa Laboratories fell after reporting its Q4 fiscal 2026 results. Sales and earnings came in below Wall Street's expected earnings, but the business did report strong growth for adjusted operating income.

LAKEWOOD, Colo., May 27, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its fourth fiscal quarter (“4Q26”) and fiscal year (“FY26”) ended March 31, 2026 (amounts in thousands).

LAKEWOOD, Colo., May 05, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the fourth quarter and the fiscal year ended March 31, 2026 at approximately 6:00 A.M. Eastern Time (ET) on Wednesday, May 27, 2026.

Five of the Fund's 10 equity sectors made a positive impact on calendar year performance, led by Industrials, Financials, and Information Technology. Alamos Gold's positive earnings outlook, a renewed stock buyback program, and rising gold prices all helped its stock to climb throughout 2025. Management reported a 48% increase in total revenue for 1Q25 compared to 1Q24, driven by OCS liver and heart transplants.

Mesa Laboratories, Inc. (MLAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

LAKEWOOD, Colo., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 16, 2026, to shareholders of record at the close of business on February 28, 2026.

LAKEWOOD, Colo., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced that Gary Owens, President and CEO, and John Sakys, CFO will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14th, 2026. Management will participate in a Formal Presentation at 4:30 p.m. Pacific Time.

LAKEWOOD, Colo., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) today announced that Gary Owens, President and CEO, and John Sakys, CFO will be attending the following upcoming conferences:

LAKEWOOD, Colo., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the second quarter of fiscal year 2026 following market close on Thursday, November 6, 2025.